MedTrace Logo

Biomarkers in Polyradiculoneuropathies

NCT04249752 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2020-01-31

No results posted yet for this study

Summary

The nodes of Ranvier contain ion channels that enable the rapid propagation of the nerve impulse. Cell adhesion molecules and glycolipids play an important role in the formation of the nodes of Ranvier. Antibodies against glycolipids are detected in half of patients with Guillain-Barré syndrome, an acute inflammatory neuropathy affecting peripheral nerve. The investigators found that antibodies target cell adhesion molecules at nodes of Ranvier in 10% of patients with chronic inflammatory demyelinating neuropathy (CIDP), another disabling neuromuscular disease affecting peripheral nerves. In the majority of patients with GBS or CIDP, the mechanisms responsible for the neuromuscular disorders are unknown. Our goals are to identify novel targets of antibodies in patients, this in order to find novel bio-markers and to better understand the physiopathology of inflammatory neuropathies. This work will help patient diagnosis and treatment orientation.

Conditions

  • Guillain-Barre Syndrome
  • CIDP

Sponsors & Collaborators

  • CHU de la Timone, Marseille, France

    collaborator UNKNOWN

  • CHU Carémeau, Nîmes, France

    collaborator UNKNOWN

  • University Hospital, Bordeaux

    collaborator OTHER

  • Centre hospitalier de Perpignan

    collaborator OTHER

  • CH de Narbonne, France

    collaborator UNKNOWN

  • CH de Béziers France

    collaborator UNKNOWN

  • University Hospital, Montpellier

    lead OTHER

Principal Investigators

  • Guillaume Taieb, MD · UH MONTPELLIER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-01
Primary Completion
2022-01-01
Completion
2025-01-30

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04249752 on ClinicalTrials.gov